Nanoparticle albumin-bound paclitaxel-based neoadjuvant regimen: A promising treatment option for HER2-low-positive breast cancer

被引：7

作者：

Shi, Wenjie ^{[1
]}

Wan, Xinyu ^{[1
]}

Wang, Ye ^{[1
]}

He, Jinzhi ^{[1
]}

Huang, Xiaofeng ^{[1
]}

Xu, Yinggang ^{[1
]}

Zhang, Weiwei ^{[1
]}

Chen, Rui ^{[1
]}

Wang, Lexin ^{[1
]}

Zheng, Ran ^{[1
]}

Ma, Lingjun ^{[1
]}

Li, Xuan ^{[1
]}

Xu, Lu ^{[2
]}

Zha, Xiaoming ^{[1
]}

Wang, Jue ^{[1
]}

机构：

[1] Nanjing Med Univ, Affiliated Hosp 1, Dept Breast Dis, 300 Guangzhou Rd, Nanjing 210000, Peoples R China

[2] Nanjing Med Univ, Affiliated Hosp 1, Dept Clin Nutr, 300 Guangzhou Rd, Nanjing 210000, Peoples R China

来源：

NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE | 2023年 / 49卷

关键词：

Paclitaxel; Nanoparticle albumin-bound paclitaxel; HER2-low-positive breast cancer; Neoadjuvant systemic therapy; Pathological complete response; DOSE-DENSE; NAB-PACLITAXEL; SOLID TUMORS; CHEMOTHERAPY; TRIAL; THERAPY; WOMEN;

D O I：

10.1016/j.nano.2023.102666

中图分类号：

TB3 [工程材料学];

学科分类号：

0805 ; 080502 ;

摘要：

This study aimed to compare the efficacy of neoadjuvant systemic therapy (NST) with solvent-based paclitaxel (Sb-P), liposomal paclitaxel (Lps-P), nanoparticle albumin-bound paclitaxel (Nab-P), and docetaxel in human epidermal growth factor receptor 2 (HER2)-low-positive and HER2-zero breast cancers. A total of 430 patients receiving 2-weekly dose-dense epirubicin and cyclophosphamide (EC) followed by 2weekly paclitaxel (Sb-P, Lps-P, or Nab-P), or 3-weekly EC followed by 3-weekly docetaxel for NST were enrolled in the study. In HER2-lowpositive patients, the pathological complete response (pCR) rate in Nab-P group was significantly higher than that in the other three paclitaxel groups (2.8 % in Sb-P group, 4.7 % in Lps-P group, 23.2 % in Nab-P group and 3.2 % in docetaxel group, p < 0.001). In HER2-zero patients, the pCR rate did not differ significantly among the four paclitaxel groups (p = 0.278). The NST regimen containing Nab-P could be considered a promising treatment option in HER2-low-positive breast cancer. (c) 2023 Published by Elsevier Inc.

引用

页数：9

共 36 条

[1] Chemotherapy (CT) and hormonotherapy (HT) as neoadjuvant treatment in luminal breast cancer patients: results from the GEICAM/2006-03, a multicenter, randomized, phase-II study [J].

Alba, E. ;

Calvo, L. ;

Albanell, J. ;

De la Haba, J. R. ;

Arcusa Lanza, A. ;

Chacon, J. I. ;

Sanchez-Rovira, P. ;

Plazaola, A. ;

Lopez Garcia-Asenjo, J. A. ;

Bermejo, B. ;

Carrasco, E. ;

Lluch, A. .

ANNALS OF ONCOLOGY, 2012, 23 (12) :3069-3074

[2] Long-term prognostic significance of HER2-low and HER2-zero in node-negative breast cancer [J].

Almstedt, Katrin ;

Heimes, Anne-Sophie ;

Kappenberg, Franziska ;

Battista, Marco J. ;

Lehr, Hans-Anton ;

Krajnak, Slavomir ;

Lebrecht, Antje ;

Gehrmann, Mathias ;

Stewen, Kathrin ;

Brenner, Walburgis ;

Weikel, Wolfgang ;

Rahnenfuehrer, Joerg ;

Hengstler, Jan G. ;

Hasenburg, Annette ;

Schmidt, Marcus .

EUROPEAN JOURNAL OF CANCER, 2022, 173 :10-19

[3] Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: First report of intergroup trial C9741/cancer and leukemia group B trial 9741 [J].

Citron, ML ;

Berry, DA ;

Cirrincione, C ;

Hudis, C ;

Winer, EP ;

Gradishar, WJ ;

Davidson, NE ;

Martino, S ;

Livingston, R ;

Ingle, JN ;

Perez, EA ;

Carpenter, J ;

Hurd, D ;

Holland, JF ;

Smith, BL ;

Sartor, CI ;

Leung, EH ;

Abrams, J ;

Schilsky, RL ;

Muss, HB ;

Norton, L .

JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (08) :1431-1439

[4] Tailoring therapies-improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015 [J].

Coates, A. S. ;

Winer, E. P. ;

Goldhirsch, A. ;

Gelber, R. D. ;

Gnant, M. ;

Piccart-Gebhart, M. ;

Thuerlimann, B. ;

Senn, H. -J. .

ANNALS OF ONCOLOGY, 2015, 26 (08) :1533-1546

[5] Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis [J].

Cortazar, Patricia ;

Zhang, Lijun ;

Untch, Michael ;

Mehta, Keyur ;

Costantino, Joseph P. ;

Wolmark, Norman ;

Bonnefoi, Herve ;

Cameron, David ;

Gianni, Luca ;

Valagussa, Pinuccia ;

Swain, Sandra M. ;

Prowell, Tatiana ;

Loibl, Sibylle ;

Wickerham, D. Lawrence ;

Bogaerts, Jan ;

Baselga, Jose ;

Perou, Charles ;

Blumenthal, Gideon ;

Blohmer, Jens ;

Mamounas, Eleftherios P. ;

Bergh, Jonas ;

Semiglazov, Vladimir ;

Justice, Robert ;

Eidtmann, Holger ;

Paik, Soonmyung ;

Piccart, Martine ;

Sridhara, Rajeshwari ;

Fasching, Peter A. ;

Slaets, Leen ;

Tang, Shenghui ;

Gerber, Bernd ;

Geyer, Charles E., Jr. ;

Pazdur, Richard ;

Ditsch, Nina ;

Rastogi, Priya ;

Eiermann, Wolfgang ;

von Minckwitz, Gunter .

LANCET, 2014, 384 (9938) :164-172

[6] Fluorouracil and dose-dense chemotherapy in adjuvant treatment of patients with early-stage breast cancer: an open-label, 2 x 2 factorial, randomised phase 3 trial [J].

Del Mastro, Lucia y ;

De Placido, Sabino ;

Bruzzi, Paolo ;

De Laurentiis, Michele ;

Boni, Corrado ;

Cavazzini, Giovanna ;

Durando, Antonio ;

Turletti, Anna ;

Nistico, Cecilia ;

Valle, Enrichetta ;

Garrone, Ornella ;

Puglisi, Fabio ;

Montemurro, Filippo ;

Barni, Sandro ;

Ardizzoni, Andrea ;

Gamucci, Teresa ;

Colantuoni, Giuseppe ;

Giuliano, Mario ;

Gravina, Adriano ;

Papaldo, Paola ;

Bighin, Claudia ;

Bisagni, Giancarlo ;

Forestieri, Valeria ;

Cognetti, Francesco .

LANCET, 2015, 385 (9980) :1863-1872

[7] Clinical and molecular characteristics of HER2-low-positive breast cancer: pooled analysis of individual patient data from four prospective, neoadjuvant clinical trials [J].

Denkert, Carsten ;

Seither, Fenja ;

Schneeweiss, Andreas ;

Link, Theresa ;

Blohmer, Jens-Uwe ;

Just, Marianne ;

Wimberger, Pauline ;

Forberger, Almuth ;

Tesch, Hans ;

Jackisch, Christian ;

Schmatloch, Sabine ;

Reinisch, Mattea ;

Solomayer, Erich F. ;

Schmitt, Wolfgang D. ;

Hanusch, Claus ;

Fasching, Peter A. ;

Luebbe, Kristina ;

Solbach, Christine ;

Huober, Jens ;

Rhiem, Kerstin ;

Marme, Frederik ;

Reimer, Toralf ;

Schmidt, Marcus ;

Sinn, Bruno, V ;

Janni, Wolfgang ;

Stickeler, Elmar ;

Michel, Laura ;

Stoetzer, Oliver ;

Hahnen, Eric ;

Furlanetto, Jenny ;

Seiler, Sabine ;

Nekljudova, Valentina ;

Untch, Michael ;

Loibl, Sibylle .

LANCET ONCOLOGY, 2021, 22 (08) :1151-1161

[8] New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1) [J].

Eisenhauer, E. A. ;

Therasse, P. ;

Bogaerts, J. ;

Schwartz, L. H. ;

Sargent, D. ;

Ford, R. ;

Dancey, J. ;

Arbuck, S. ;

Gwyther, S. ;

Mooney, M. ;

Rubinstein, L. ;

Shankar, L. ;

Dodd, L. ;

Kaplan, R. ;

Lacombe, D. ;

Verweij, J. .

EUROPEAN JOURNAL OF CANCER, 2009, 45 (02) :228-247

[9] Examination of Low ERBB2 Protein Expression in Breast Cancer Tissue [J].

Fernandez, Aileen, I ;

Liu, Matthew ;

Bellizzi, Andrew ;

Brock, Jane ;

Fadare, Oluwole ;

Hanley, Krisztina ;

Harigopal, Malini ;

Jorns, Julie M. ;

Kuba, M. Gabriela ;

Ly, Amy ;

Podoll, Mirna ;

Rabe, Kimmie ;

Sanders, Mary Ann ;

Singh, Kamaljeet ;

Snir, Olivia L. ;

Soong, T. Rinda ;

Wei, Shi ;

Wen, Hannah ;

Wong, Serena ;

Yoon, Esther ;

Pusztai, Lajos ;

Reisenbichler, Emily ;

Rimm, David L. .

JAMA ONCOLOGY, 2022, 8 (04) :607-610

[10] Comparing Neoadjuvant Nab-paclitaxel vs Paclitaxel Both Followed by Anthracycline Regimens in Women With ERBB2/HER2-Negative Breast Cancer-The Evaluating Treatment With Neoadjuvant Abraxane (ETNA) Trial A Randomized Phase 3 Clinical Trial [J].

Gianni, Luca ;

Mansutti, Mauro ;

Anton, Antonio ;

Calvo, Lourdes ;

Bisagni, Giancarlo ;

Bermejo, Begona ;

Semiglazov, Vladimir ;

Thill, Marc ;

Ignacio Chacon, Jose ;

Chan, Arlene ;

Morales, Serafin ;

Alvarez, Isabel ;

Plazaola, Arrate ;

Zambetti, Milvia ;

Redfern, Andrew D. ;

Dittrich, Christian ;

Dent, Rebecca Alexandra ;

Magazzu, Domenico ;

De Fato, Raffaella ;

Valagussa, Pinuccia ;

Tusquets, Ignacio .

JAMA ONCOLOGY, 2018, 4 (03) :302-308

← 1 2 3 4 →